Clinical trial of birtamimab in patients with stage IV light chain amyloidosis at the Mayo Clinic

THE PURPOSE OF THIS STUDY IS TO EVALUATE WHETHER BIRTAMIMAB WILL IMPROVE SURVIVAL IN PATIENTS WITH STAGE IV AL AMYLOIDOSIS AT THE MAYO CLINIC. THIS IS A RELATIVELY RARE BLOOD DISEASE IN WHICH ABNORMAL PROTEIN DEPOSITS, CALLED AMYLOID, CAN ACCUMULATE IN ORGANS AND CAUSE PROGRESSIVE DAMAGE SO THAT THEY NO LONGER FUNCTION PROPERLY. ORGANS THAT MAY BE AFFECTED INCLUDE THE HEART, KIDNEYS, LIVER, SPLEEN, DIGESTIVE OR GASTROINTESTINAL TRACT AND NERVOUS SYSTEM.